Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health

Group 1 - Kenvue Inc. (NYSE:KVUE) is considered a promising stock, but recent macroeconomic challenges have led to lowered price targets by analysts [1][3] - Jefferies analyst Keith Devas reduced Kenvue's price target from $25 to $23 while maintaining a Buy rating, citing impacts on consumer health stocks [1] - Deutsche Bank analyst Stephen Powers also lowered Kenvue's price target from $20 to $18, assigning a Hold rating [2] Group 2 - Kenvue operates as a consumer health company across multiple regions, including the US, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [4] - The company has three operational segments: Self Care, Skin Health and Beauty, and Essential Health [4] - Jeff Smith, a board member and CEO of Starboard Value, indicated that Kenvue is focused on maximizing shareholder value through collaboration between management and the board [3]